The FDA has approved Gilead’s long-anticipated HIV prevention shot, Yeztugo, offering a twice-a-year alternative to daily pills, according to USA TODAY. Priced at over $28,000 annually, the injectable aims to improve adherence by reducing how often it must be taken.
Clinical trials showed the drug was up to 100% effective in some populations, with significantly lower infection rates than daily pills. Experts say the simplicity of semiannual dosing could help reach underserved groups and those with inconsistent access to care.
Gilead plans to work with insurers to ensure coverage. Advocates call it a global game changer in HIV prevention, especially for people struggling with stigma, mental health issues, or access to consistent health services.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].